NCT07264725已完成不适用
Multiple Sclerosis Care in a Conflict-Affected Health System: Diagnostic Delay, Treatment Access, and Disability Outcomes in Libya
University of Zintan1 个研究点 分布在 1 个国家目标入组 369 人开始时间: 2023年8月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 369
- 试验地点
- 1
- 主要终点
- Moderate-to-Severe Disability (EDSS ≥3.0)
研究概览
简要总结
This study aims to understand differences in access to diagnosis and treatment for people with multiple sclerosis (MS) receiving care in Libya. The study uses data from the Libyan Multiple Sclerosis Registry, which collects clinical and treatment information from patients at two tertiary neurology centres. The main focus is to examine how long it takes for patients to receive an MS diagnosis, who has access to high-efficacy disease-modifying therapies, and how these factors relate to disability levels. The results will help identify gaps in MS care within a conflict-affected health system and guide improvements in services for patients in Libya.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults aged 18 years or older
- •Diagnosis of multiple sclerosis according to the 2017 McDonald criteria
- •Receiving care at Tripoli University Hospital or Omar Askar Hospital
- •Able to provide written informed consent
- •Recorded EDSS score at registry entry
- •Availability of core demographic and diagnostic information
排除标准
- •Clinically isolated syndrome (CIS)
- •Age younger than 18 years
- •Absence of confirmed multiple sclerosis diagnosis
- •Missing key clinical variables required for primary analysis (EDSS, phenotype, or DMT information)
- •Declined or unable to provide informed consent
结局指标
主要结局
Moderate-to-Severe Disability (EDSS ≥3.0)
时间窗: At registry entry
次要结局
- EDSS Ordinal Disability Categories(At registry entry)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Multicenter, single-blind (subject), active control comparison, randomization, non-inferiority, sponsor Initiated Trials to confirm the hemostatic effect and safety of 'CEGP003' in patients with bleeding during hemorrhagic non-variceal upper gastrointestinal bleeding procedureDiseases of the digestive systemKCT0004655CGBio218
进行中（未招募）
不适用
International trial involving numerous sites in several countries to investigate the efficacy in shortening diarrhoea and safety for small children (infants and toddlers) by treatment with Lactobacillus rhamnosus GG (brand name: InfectoDiarrstop LGG Mono)EUCTR2012-002291-13-PLInfectoPharm - Arzneimittel und Consilium GmbH150
进行中（未招募）
不适用
International trial involving numerous sites in several countries to investigate the efficacy in shortening diarrhoea and safety for small children (infants and toddlers) by treatment with Lactobacillus rhamnosus GG (brand name: InfectoDiarrstop LGG Mono Beutel)EUCTR2012-002291-13-DEInfectoPharm - Arzneimittel und Consilium GmbH150
进行中（未招募）
不适用
Multicentre, randomised, double-blind (double-dummy), active comparator-controlled, phase III study of the efficacy and safety of a single s.c. Diclofenac HPBCD 75mg/1ml injection as compared to a single i.m. Voltarol® 75mg/3ml, in the treatment of acute moderate-to-severe post-surgical pain following dental surgery (impacted 3rd molar removal).EUCTR2009-011980-35-GBIBSA Institut Biochimique SA150
进行中（未招募）
不适用
Multicentre, randomized, double-blind, active comparator-and placebo-controlled, parallel-group phase III clinical study for the evaluation of Diclofenac HPBCD 25, 50 mg/ml administered as a single s.c. dose, in the treatment of acute moderate-to-severe post-surgical pain from dental surgery (impacted 3rd molar extraction)acute moderate-to-severe post-surgical pain from dental surgery (impacted 3rd molar extraction)MedDRA version: 9.1Level: HLTClassification code 10044049Term: Dental pain and sensation disordersEUCTR2009-011663-37-GBIBSA, Institut Biochimique SA300